bih.button.backtotop.text
HomeLab Services GuideTests
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Z
Clear
Overview
ข้อมูลทั่วไป Specimen
ข้อมูลสิ่งส่งตรวจ Performance
ข้อมูลการทดสอบ Clinical & Interpretation
ข้อมูลทางคลินิก
 
Test Code (รหัสการทดสอบ):
090-30-1390-01
Order Name (ชื่อการทดสอบ):
Cyclosporine Level
 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ K3 EDTA (Lavender Top) 3 mL,  1 tube
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 3 hours 
 
Useful For (ประโยชน์การทดสอบ):
Determination of cyclosporine in human whole blood.
Cyclosporine assay is used as an aid in the management of heart, liver and kidney transplant patients receiving cyclosporine therapy.
 
Methodology (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
 
 
Test Code (รหัสการทดสอบ):
090-30-1390-01
Order Name (ชื่อการทดสอบ):
Cyclosporine Level
 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ K3 EDTA (Lavender Top) 3 mL,  1 tube
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
EDTA Whole blood, minimum volume 1 mL
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic vial
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
EDTA Whole blood Refrigerated, 2oC to 8oC 7 days
Frozen, -20oC 14 days
 
 
 
Test Code (รหัสการทดสอบ):
090-30-1390-01
Order Name (ชื่อการทดสอบ):
Cyclosporine Level
 
Method detail (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
Schedule (ตารางการทดสอบ):
Tested daily (24 hours)
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 3 hours 
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time (ระยะเวลาเก็บสิ่งส่งตรวจ):
5 days
 
 
 
Test Code (รหัสการทดสอบ):
090-30-1390-01
Order Name (ชื่อการทดสอบ):
Cyclosporine Level
 
 
Clinical Information (ข้อมูลทางคลินิก):
Cyclosporine is a cyclic undecapeptide of fungal origin and a potent immunosuppressant. It is used as a primary agent during immunosuppressive therapy for solid organ transplants. Immunosuppression is thought to be the result of impairment of T-cell receptor transcription of the IL-2 gene. Cyclosporine therapy has greatly improved organ transplant survival of heart, liver and kidney transplants. Cyclosporine may be administered by IV or orally. Absorption from  the gastrointestinal tract is variable, unpredictable, and incomplete. Bioavailability increases during treatment so oral doses must be gradually  reduced in order to maintain a constant cyclosporine concentration in the blood. Assessment of cyclosporine concentrations in blood aids in adjusting patients’ dosage and avoids cyclosporine underdosage inefficacy or overdosage toxicity.  Cyclosporine is eliminated almost completely by hepatic metabolism; cytochrome P-450 enzymes being responsible for
the biotransformation of cyclosporine and its metabolites. More than thirty metabolites have been identified.       

Preliminary data indicate cyclosporine metabolites are less immunosuppressive and less toxic than their parent compound. The use of cyclosporine is associated with serious toxic side effects, primarily nephrotoxicity and hepatotoxicity Other adverse effects include diarrhea, gum hyperplasia, nausea, vomiting, hirsutism, tremor, and hypertension. Some studies have shown the benefits of monitoring cyclosporine concentrations, including a reduction in the incidence of biopsy proven acute rejection.
 
Reference Value (ค่าอ้างอิง):
Trough level: 100 – 400 ng/mL
 
Clinical Reference (เอกสารอ้างอิง):
  1. Manufacturer’s Reagent package inserts, Cyclosporine, Abbott Laboratories, Abbott Park, IL 60064, USA.
  2. Reference intervals: UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Retrieved: July2018)